Kailera Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
KLRA$14.24+3.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands) (unaudited)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(285,837) | $(86,553) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 303 | 188 |
| Stock-based compensation expense | 22,204 | 7,423 |
| Change in fair value of preferred stock tranche right liability | — | (1,400) |
| Non-cash lease expense | 833 | 354 |
| Accretion of discounts on investments, net | (5,246) | (1,134) |
| Change in fair value of convertible promissory notes | — | 2,781 |
| Other | (13) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (7,120) | (7,715) |
| Non-current clinical deposits | (1,944) | — |
| Other non-current assets | 2,343 | 67 |
| Accounts payable | 2,075 | (38) |
| Accrued expenses and other current liabilities | (6,119) | 12,318 |
| Operating lease liabilities | (781) | (421) |
| Other non-current liabilities | (203) | — |
| Net cash used in operating activities | (279,505) | (74,130) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (443) |
| Purchases of marketable securities | (775,319) | (178,892) |
| Maturities of marketable securities | 337,970 | 77,205 |
| Net cash used in investing activities | (437,349) | (102,130) |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of stock options | 826 | — |
| Proceeds from issuance of convertible promissory notes | — | 100,000 |
| Proceeds from issuance of common stock, net of commissions and underwriting discounts | 668,438 | — |
| Payments of deferred offering costs | (6,140) | (243) |
| Net cash provided by financing activities | 663,124 | 99,757 |
| Net decrease in cash, cash equivalents and restricted cash | (53,730) | (76,503) |
| Cash, cash equivalents and restricted cash at beginning of period | 161,028 | 175,178 |
| Cash, cash equivalents and restricted cash at end of period | $107,298 | $98,675 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $106,537 | $97,914 |
| Restricted cash | 761 | 761 |
| Total cash, cash equivalents and restricted cash | $107,298 | $98,675 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock to common stock | $992,364 | $— |
| Deferred offering costs included in accounts payable and accrued expenses | $— | $733 |
| Purchases of property and equipment included in accounts payable and accrued expenses | $— | $215 |
| Increase in right-of-use assets and operating lease liabilities from lease modifications | $— | $32 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.